基于国际预后指数的弥漫大B细胞淋巴瘤免疫预后模型数据表4

数据集获取（Figshare）

• 源站标题：DataSheet_4_International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.xlsx
• DOI：10.3389/fimmu.2021.732006.s004
• 发布日期：2021-10-22
• 文件数：1 个
• 文件总体积：832.16 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/DataSheet_4_International_Prognostic_Index-Based_Immune_Prognostic_Model_for_Diffuse_Large_B-Cell_Lymphoma_xlsx/16852207

命令行下载

curl -L -o "DataSheet_4_International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.xlsx" "https://ndownloader.figshare.com/files/31156399"

文件清单

• DataSheet_4_International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.xlsx（832.16 KB）

文件总体积 832.16 KB（源站 API 实测）。

数据说明

BackgroundThe International Prognostic Index (IPI) is widely used to discriminate the prognosis of patients with diffuse large B-cell lymphoma (DLBCL). However, there is a significant need to identify novel valuable biomarkers in the context of targeted therapy, such as immune checkpoint blockade (ICB).
MethodsGene expression data and clinical DLBCL information were obtained from The Cancer Genome Atlas and Gene Expression Omnibus datasets. A total of 371 immune-related genes in DLBCL patients associated with different IPI risk groups were identified by weighted gene co-expression network analysis, and eight genes were selected to construct an IPI-based immune prognostic model (IPI-IPM). Subsequently, we analyzed the somatic mutation and transcription profiles of the IPI-IPM subgroups as well as the potential clinical response to immune checkpoint blockade (ICB) in IPI-IPM subgroups.
ResultsThe IPI-IPM was constructed based on the expression of CMBL, TLCD3B, SYNDIG1, ESM1, EPHA3, HUNK, PTX3, and IL12A, where high-risk patients had worse overall survival than low-risk patients, consistent with the results in the independent validation cohorts. The comprehensive results showed that high IPI-IPM risk scores were correlated with immune-related signaling pathways, high KMT2D and CD79B mutation rates, and upregulation of inhibitory immune checkpoints, including PD-L1, BTLA, and SIGLEC7, indicating a greater potential response to ICB therapy.
ConclusionThe IPI-IPM has independent prognostic significance for DLBCL patients, which provides an immunological perspective to elucidate the mechanisms of tumor progression and sheds light on the development of immunotherapy for DLBCL.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fimmu.2021.732006.s004（source: https://frontiersin.figshare.com/articles/dataset/DataSheet_4_International_Prognostic_Index-Based_Immune_Prognostic_Model_for_Diffuse_Large_B-Cell_Lymphoma_xlsx/16852207）。